

HEPATITIS C CASCADE OF CARE IN HIV/HCV-COINFECTED PERSONS IN EUROPE IN THE DAA ERA

Olga Fursa on behalf of the EuroSIDA study group

*Centre of Excellence for Health, Immunity and Infections
Copenhagen, Denmark*

Disclosure: None

INTRODUCTION

BACKGROUND:

WHO Global Health Sector Strategy on Viral Hepatitis includes the targets of:


- ▶ diagnosing **90%** of chronic hepatitis infections, and
- ▶ **80%** treatment coverage among eligible individuals with chronic HCV by **2030**.

DAA treatment leads to sustained virological response in **≥95% persons with HCV**.

Treatment prioritized in the **HIV/HCV-coinfected** group.
DAA availability differs by region and country.

STUDY OBJECTIVES:

- ▶ To describe the hepatitis C cascade of care in HIV/HCV coinfected individuals in Europe under follow up in **2018**
- ▶ To compare regional and intra-regional differences in the cascade of care in terms of reaching the WHO targets



METHODS

- ▶ People living with HIV in the EuroSIDA cohort who had an anti-HCV antibody positive test result and were under prospective follow-up at **1/10/2018** were included in the study;
- ▶ The study design was based on the previous HCV cascade of care constructed by *Amele et al.* that included participants under follow-up in **2015***, before the widespread DAA use;
- ▶ A nine-stage cascade of care built **for the overall coinfectd cohort, by region and by country** (for **20** countries that together contributed to **93.7%** of all study participants)

STUDY POPULATION:

- ▶ **5,080** anti-HCV+ PLHIV from **33** European countries
- ▶ **3,605** (71%) male
- ▶ Median age of **50** years (IQR **42-56**)
- ▶ On ART: **4,941** (97.3%)
- ▶ HIV viral load below **200** copies/mL in **4,694** (92.4%)
- ▶ Liver fibrosis: F0/F1 – **3,583** (70.5%), F4 – **492** (9.7%)


DIAGNOSTIC STAGES	
1	anti-HCV antibody positive
2	ever HCV RNA tested
3	currently HCV RNA positive
TREATMENT STAGES	
4a**	ever chronically infected with HCV
4b	ever diagnosed with chronic HCV
5	ever started treatment
6	treatment completed
7**	sufficient follow-up after treatment
8	follow-up HCV RNA available
9	cured

*Amele S, Peters L, Sluzhynska M, et al. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA. *HIV Med.* 2019;20(4):264-273. doi:10.1111/hiv.12711


** new HCV CoC stages added to the CoC described by Amele et al.

HCV CoC IN EUROPE, BY REGION

Diagnostic stages



Treatment stages



■ All (5080)
■ South (1171)
■ Central-West (1237)
■ North (776)
■ Central-East (760)
■ East (1136)
■ All (4562)
■ South (1069)
■ Central-West (1087)
■ North (702)
■ Central-East (666)
■ East (1037)

- ▶ More than **93%** of the estimated number of chronic infections have ever been diagnosed in all regions, except Eastern Europe;
- ▶ In Southern and Central-Western regions, **>80%** ever chronically HCV infected PLHIV have ever received treatment, while the proportion with cured HCV infection did not exceed **80%** in any region.


HCV CoC IN EUROPE, BY COUNTRY

HCV DIAGNOSIS:

- ▶ Over **90%** anti-HCV AB positive PLHIV ever tested for HCV RNA in **17** of **20** countries (except for **28.6%** tested in Belarus, **86.7%** in Russia, and **87.9%** in Hungary);
- ▶ Of the estimated number of chronic HCV infections, over **90%** have been diagnosed in all, except the same three countries.

HCV TREATMENT:

- ▶ In **7** out of **20** countries, over **80%** of the estimated number of chronically infected ever started anti-HCV treatment (Austria, Belgium, France, Georgia, Portugal, Spain and the UK);
- ▶ The proportion of HCV cure ranged from **6.7%** of the estimated number of chronically infected in Belarus to **87.2%** in Austria;
- ▶ Western European countries still perform better than Eastern European, with an exception of Georgia;
- ▶ The largest intra-regional heterogeneity observed in Eastern and Central-Western Europe.



CONCLUSIONS

- ▶ In an HIV/HCV co-infected population, over **90%** of the chronic HCV infections have been diagnosed in all EuroSIDA regions except Eastern Europe, and over **80%** of persons with chronic HCV started treatment in Southern and Central-Western Europe;
- ▶ On a country level, over **90%** of chronic infections have been diagnosed in **17** out of **20** countries, and over **80%** persons with chronic HCV started treatment against HCV in **7** countries;
- ▶ The proportion of HCV cure among the estimated number of chronically infected exceeded **70%** in **4** countries and was over **80%** only in Austria.
- ▶ More effort is needed to increase the HCV RNA testing coverage in Eastern Europe and the treatment coverage in the majority of the European countries.



ACKNOWLEDGEMENTS

Writing group: Olga Fursa, Amanda Mocroft, Jeffrey V. Lazarus, Sarah Amele, Jens Lundgren, Raimonda Matulionyte, Line D. Rasmussen, Jürgen K. Rockstroh, Milosz Parczewski, David Jilich, Santiago Moreno, Anna Vassilenko, Karine Lacombe, Lars Peters, EuroSIDA study group